Recurrent erythema multiforme: A therapeutic proposal for a chronic disease
- 5 July 2021
- journal article
- research article
- Published by Wiley in The Journal of Dermatology
- Vol. 48 (10) , 1569-1573
Abstract
Recurrent erythema multiforme is a chronic relapsing disease that represents a therapeutic challenge. Our objective was to retrospectively evaluate the clinical–epidemiological characteristics and therapeutic response of patients with recurrent erythema multiforme and suggest a therapeutic protocol. We included patients with recurrent erythema multiforme diagnosed between January 2000 and December 2019. Clinical symptoms and a positive serology for herpes simplex virus were the inclusion criteria to initiate acyclovir in monotherapy or a combined treatment with dapsone, thalidomide, or immunosuppressants in refractory cases. Thirty‐five patients were included and 71.4% were female. The median disease onset age was 35.7 years and the mean follow‐up was 7.58 years. The skin was the most affected site (91.4%). Herpes simplex virus immunoglobulin (Ig)G serology was positive in 91.1% of cases. Acyclovir treatment was used in 33 of 35 patients, and complete remission was achieved in 22 of 33 after the first therapeutic course; 16 of 22 relapsed and required a second acyclovir cycle. Combined treatment with dapsone was required in nine of 33 due to partial response to acyclovir; thalidomide was an adjuvant drug in four of 33 due to adverse effects to dapsone. After the first cycle of acyclovir with or without combined therapy, 19 of 33 patients relapsed and received 2–6 additional cycles. Our results suggest that recurrent erythema multiforme presents a good response to acyclovir in monotherapy or in combined therapy with dapsone or thalidomide in the majority of patients. We propose a long‐term therapeutic protocol to enable disease remission.Keywords
This publication has 15 references indexed in Scilit:
- Efficacy of interferon in recurrent valaciclovir-refractory erythema multiforme in a patient not infected with hepatitis C virusClinical and Experimental Dermatology, 2016
- Recurrent erythema multiforme: Clinical characteristics, etiologic associations, and treatment in a series of 48 patients at Mayo Clinic, 2000 to 2007Journal of the American Academy of Dermatology, 2010
- A double-blind, placebo-controlled trial of continuous acyclovir therapy in recurrent erythema multiformeBritish Journal of Dermatology, 2006
- Correlations Between Clinical Patterns and Causes of Erythema Multiforme Majus, Stevens-Johnson Syndrome, and Toxic Epidermal NecrolysisArchives of Dermatology, 2002
- Herpes Simplex Virus Associated Erythema Multiforme (HAEM) is Mechanistically Distinct from Drug-Induced Erythema Multiforme: Interferon-γ is Expressed in HAEM Lesions and Tumor Necrosis Factor-α in Drug-Induced Erythema Multiforme LesionsJournal of Investigative Dermatology, 1999
- Characteristics of the oral lesions in patients with cutaneous recurrent erythema multiformeJournal of Oral Pathology & Medicine, 1995
- Recurrent erythema multiforme: tissue typing in a large series of patientsBritish Journal of Dermatology, 1994
- A Case of Herpes‐associated Erythema Multiforme in a Japanese ChildThe Journal of Dermatology, 1993
- Detection of HSV-specific DNA in biopsy tissue of patients with erythema multiforme by polymerase chain reactionBritish Journal of Dermatology, 1992
- Acyclovir for recurrent erythema multiforme caused by herpes simplexJournal of the American Academy of Dermatology, 1988